| 18.15 -0.53 (-2.84%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 22.15  |
1-year : | 25.22 |
| Resists | First : | 18.96 |
Second : | 21.6 |
| Pivot price | 18.97 |
|||
| Supports | First : | 14.71 |
Second : | 12.24 |
| MAs | MA(5) : | 18.31 |
MA(20) : | 18.91 |
| MA(100) : | 15.37  |
MA(250) : | 9.07 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 23.4 |
D(3) : | 21 |
| RSI | RSI(14): 51.2 |
|||
| 52-week | High : | 24.28 | Low : | 1.33 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ERAS ] has closed above bottom band by 25.0%. Bollinger Bands are 46.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 18.97 - 19.08 | 19.08 - 19.16 |
| Low: | 17.45 - 17.6 | 17.6 - 17.71 |
| Close: | 17.93 - 18.14 | 18.14 - 18.32 |
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Fri, 31 Jul 2026
Robbins LLP Reminds Erasca, Inc. Investors of the Pending - GlobeNewswire
Fri, 31 Jul 2026
ERAS DEADLINE: The Gross Law Firm Reminds Erasca, Inc. Investors of Upcoming Securities Class Action Deadline - GlobeNewswire
Thu, 30 Jul 2026
Price to sales forward of Erasca, Inc. – NASDAQ:ERAS - TradingView
Thu, 30 Jul 2026
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 10, 2026 in Erasca, Inc. Lawsuit - ERAS - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 347 (M) |
| Shares Float | 248 (M) |
| Held by Insiders | 9.6 (%) |
| Held by Institutions | 85.3 (%) |
| Shares Short | 30,770 (K) |
| Shares Short P.Month | 31,490 (K) |
| EPS | -0.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.26 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -18 % |
| Return on Equity (ttm) | -69.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.38 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -91 (M) |
| Levered Free Cash Flow | -213 (M) |
| PE Ratio | -19.51 |
| PEG Ratio | 0 |
| Price to Book value | 14.28 |
| Price to Sales | 0 |
| Price to Cash Flow | -68.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|